biotech / news / / The Manila Times
Nxera to receive US$22.5 million in milestone payments from Neurocrine.
Neurocrine has begun dosing patients in a Phase 2 clinical trial of NBI-1117570 for schizophrenia.
KEY POINTS
- Nxera will receive US$22.5 million in milestone payments from Neurocrine, recognized in Q1 FY2026.
- NBI-1117570 is the second NxWave-designed muscarinic agonist in Neurocrine’s pipeline to reach Phase 2.
- The Phase 2 trial will enroll approximately 120 in-patient adults and use PANSS score as the primary endpoint.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →